Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

Published:2019-12 Issue:12 Volume:20 Page:1691-1701
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Shaw Alice T,Solomon Benjamin J,Chiari Rita,Riely Gregory J,Besse Benjamin,Soo Ross A,Kao Steven,Lin Chia-Chi,Bauer Todd M,Clancy Jill S,Thurm Holger,Martini Jean-Francois,Peltz Gerson,Abbattista Antonello,Li Sherry,Ou Sai-Hong Ignatius

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer;Davies;Clin Cancer Res,2012

2. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J Clin Oncol,2012

3. Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations;Dugay;Oncotarget,2017

4. Novel targets in non-small cell lung cancer: ROS1 and RET fusions;Gainor;Oncologist,2013

5. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer;Zeng;OncoTargets Ther,2018

Cited by 272 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

2. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

3. New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment;Discover Oncology;2024-09-13

4. Genomic and immune heterogeneity of multiple synchronous lung adenocarcinoma at different developmental stages;Nature Communications;2024-09-10

5. Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study;The Lancet Respiratory Medicine;2024-09